Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma

A. H. Morice,1 S. Peterson,2 O. Beckman,2 D. Osmanliev3

SUMMARY

Background: Budesonide/formoterol is an effective treatment for both asthma and chronic obstructive pulmonary disease. This study compared the efficacy and safety of a novel hydrofluoroalkane (HFA) pressurised metered-dose inhaler (pMDI) formulation of budesonide/formoterol with that of budesonide pMDI and budesonide/formoterol dry-powder inhaler (DPI; Turbuhaler®). Methods: This was a 12-week, multinational, randomised, double-blind, double-dummy study involving patients aged ≥ 12 years with asthma. All patients had a forced expiratory volume in 1 s of 50–90% predicted normal and were inadequately controlled on inhaled corticosteroids (500–1600 μg/day) alone. Following a 2-week run-in, during which they received their usual medication, patients were randomised (two inhalations twice daily) to budesonide pMDI 200 μg, budesonide/formoterol DPI 160/4.5 μg or budesonide/formoterol pMDI 160/4.5 μg. The primary efficacy end-point was change from baseline in morning peak expiratory flow (PEF). Results: In total, 680 patients were randomised, of whom 668 were included in the primary analysis. Therapeutically equivalent increases in morning PEF were observed with budesonide/formoterol pMDI (29.3 l/min) and budesonide/formoterol DPI (32.0 l/min) (95% confidence interval: -10.4 to 4.9; p = 0.48). The increase in morning PEF with budesonide/formoterol pMDI was significantly higher than with budesonide pMDI (+28.7 l/min; p < 0.001). Similar improvements with budesonide/formoterol pMDI vs. budesonide pMDI were seen for all secondary efficacy end-points. Both combination treatments were similarly well tolerated. Conclusions: Budesonide/formoterol, administered via the HFA pMDI or DPI, is an effective and well-tolerated treatment for adult and adolescent patients with asthma, with both devices being therapeutically equivalent.

Background

Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapies are the recommended maintenance treatment option for adults with persistent asthma (1). One such therapy is budesonide/formoterol in one dry-powder inhaler (DPI) (Symbicort®, Turbuhaler®, AstraZeneca R&D, Lund, Sweden), a combination that has been shown in numerous trials to be an effective and well-tolerated treatment for asthma (2–7).

The pharmacological properties of budesonide/formoterol mean that this combination is suitable for use in different settings. The formoterol component is associated with a rapid onset of bronchodilatory effect, similar to that of standard, short-acting β2-agonist (SABA) reliever medications, such as salbutamol (8), as well as an extended duration of action, which is comparable with that of salmeterol (9). Budesonide, on the other hand, has a prolonged dwell time in the airway tissues, resulting in a long duration of anti-inflammatory effect (10–12). These properties mean that budesonide/formoterol is effective when given once daily (2) and when used in the acute setting (13). In addition, the nature of the dose–response curves of both budesonide and formoterol (14–16) means that temporarily increasing the dose of budesonide/formoterol in response to decreasing asthma control can provide patients with additional clinical benefits without increasing the risk of adverse systemic effects. As such, budesonide/formoterol is uniquely suitable for adjustable...
maintenance dosing (3,4,17,18) and for use as main-
tenance and reliever therapy [Symbicort® Mainte-
nance and Reliever Therapy (SMART)] (5–7,19).

Although the use of DPIs, such as Turbuhaler®, is
well established, pressurised metered-dose inhalers
(pMDIs) are the most commonly used inhalation
devices in many countries worldwide (20). The
majority of available pMDI devices contain chloro-
fluorocarbon (CFC) propellants, which have well-
documented adverse effects on the atmospheric
ozone layer. Over the past few years, research has led
to the development and approval of hydrofluoroalk-
ane (HFA)-based aerosols – which do not have
ozone-depleting properties – as alternatives to CFC
propellants (21). Accordingly, budesonide/formoterol
has also been reformulated as an HFA pMDI (Symbi-
cort Rapihaler®) to provide clinicians and patients
with greater freedom to select a delivery system that
meets their needs and preferences.

The aim of this study was to compare the efficacy
and safety of the new pMDI formulation of budeso-
nide/formoterol with that of budesonide/formoterol
DPI and budesonide (Pulmicort®, AstraZeneca R&D,
Lund, Sweden) pMDI in adults and adolescents with
asthma.

Methods

Patients

Adult and adolescent outpatients (aged ≥ 12 years)
with asthma (22) for ≥ 6 months, who were inade-
quately controlled on ICS alone, were enrolled. For
inclusion, patients had to have a forced expiratory
volume in 1 s (FEV₁) ≥ 50% and ≤ 90% of predicted
normal (prebronchodilator), reversibility of ≥ 12%
FEV₁ after inhalation of terbutaline 1 mg (Bricanyl®
Turbuhaler®, AstraZeneca) and a history of daily ICS
use (stable dose of 500–1600 μg/day within 30 days
prior to enrolment) for ≥ 3 months.

Before randomisation, all patients had to have a
total asthma symptom score ≥ 1 on ≥ 4 of the last
7 days of run-in (scale: 0 = no symptoms, 1 =
aware of symptoms but can tolerate them easily,
2 = asthma causing enough discomfort to interfere
with normal activities or sleep and 3 = unable to
perform normal activities or sleep because of asthma;
day- and nighttime scores summed). The first patient
was enrolled on 30th April 2002 and the last patient
completed the study on 6th February 2003.

Study design

This was a 12-week, phase III, randomised, double-
blind, double-dummy, parallel-group study con-
ducted in 62 centres across eight countries (Brazil,
Bulgaria, Canada, Hungary, Mexico, the Philippines,
Thailand and the UK). The study complied with
Good Clinical Practice guidelines and the ethical
principles of the Declaration of Helsinki. An inde-
pendent ethics committee or institutional review
board approved the study protocol and patient con-
sent form at each centre.

Patients were instructed to stop taking their LABA
therapy for 3 days prior to the beginning of the run-
in period (visit 1). Also, those using an ICS/LABA
combination were requested to stop treatment with
the combination 3 days before visit 1 and to con-
tinue with the same ICS alone. SABA use was
restricted at 6 h prior to visit 1. During the study
period [run-in and treatment period (visits 1–5)]
any β₂-agonists other than study reliever and revers-
ibility test medication were not permitted.

Following a 10- to 14-day run-in, during which
patients continued their prestudy ICS medication
(stable dose), patients were randomised to treatment
(two inhalations twice daily) with one of the follow-
ing: budesonide pMDI 200 μg (Pulmicort® pMDI);
budesonide/formoterol DPI 160/4.5 μg (Symbicort®
Turbuhaler®); or budesonide/formoterol pMDI 160/
4.5 μg (Symbicort Rapihaler®). The doses of budeso-
nide in each group were comparable; differences are
explained by labelling changes for new inhaled drugs
that require the delivered dose to be reported rather
than the metered dose.

Patients were randomised sequentially in blocks of
six using a computer-generated randomisation sche-
dule. Eligible patients were consecutively allocated the
lowest available randomisation code. The treatment
code was only broken in the case of medical emergen-
cies. The randomisation schedule was computer gen-
erated at AstraZeneca Research and Development,
Charnwood, UK. To maintain blinding, each patient
also received a placebo device. To reduce incom-
patibility, each patient received only two of the three
devices: one active and one placebo device. An inhaled
SABA (terbutaline 0.5 mg per inhalation or equiva-

tent) was available for all patients for symptom relief.

Assessments

The primary efficacy end-point was the change in
morning peak expiratory flow (PEF) from baseline
(mean of the last 10 days of run-in) to the mean
value over the 12-week treatment period. Secondary
efficacy end-points included: change from baseline
(mean of the last 10 days of run-in) to the mean
value over the treatment period in evening PEF;
reliever medication use; reliever medication-free days;
nighttime awakenings caused by asthma; asthma
symptom score; symptom-free days (a night and day
without asthma symptoms and no nighttime awaken-
ings caused by asthma); and asthma-control days (a
night and day without asthma symptoms or reliever medication use and no nighttime awakenings caused by asthma. All PEF measurements (taken prior to inhalation of study medication using a Mini-Wright peak flow meter [Clement Clarke, Harlow, UK]), reliever medication use, nighttime awakenings caused by asthma and asthma symptom scores were recorded by patients in a daily diary.

Change from baseline (week 0) to the mean of the treatment period (weeks 2–12) in FEV₁ and change from baseline (week 0) to the end of treatment (week 12) in Asthma Quality of Life Questionnaire (standardised version) [AQLQ(S)] scores (23) were also predefined secondary end-points. FEV₁ was assessed during clinic visits at enrolment and randomisation and at 2, 6 and 12 weeks postrandomisation, according to European Respiratory Society recommendations (24,25). The 32-item AQLQ(S) was administered during clinic visits at randomisation and at weeks 2 and 12 (seven-point scale: 1 = greatest possible impairment and 7 = least impairment) (23). A change in AQLQ(S) score of ≥0.5 units was defined as a clinically relevant change (26).

Safety assessments included adverse events (assessed throughout), vital signs (assessed at enrolment, randomisation, weeks 2 and 12) and clinical laboratory parameters (haematology, clinical chemistry and urinalysis; assessed at randomisation, weeks 2 and 12).

All patients received instruction on how to use the pMDI and DPI devices and the peak flow metre before the start of the study at visit 1. Each participating study site was provided with a Turbuhaler/pMDI to be used with disposable mouthpieces/actuators, allowing patients to practise the inhalation technique.

Statistical analysis
The intent-to-treat (ITT) population (i.e. all randomised patients with postrandomisation data) was used for the main efficacy analyses. The primary objective of the study was to show that budesonide/formoterol pMDI was more efficacious than budesonide pMDI. The study was powered on this primary objective and approximately 600 evaluable patients (200 in each arm) were required for a 90% probability of detecting a true difference between budesonide/formoterol pMDI and budesonide pMDI of 13 l/min in mean change in morning PEF, assuming a standard deviation of 40 l/min (two-group t-test with a 5% two-sided significance level).

A secondary objective was to compare the efficacy of budesonide/formoterol pMDI with that of budesonide/formoterol DPI. Therapeutic equivalence between budesonide/formoterol pMDI and budesonide/formoterol DPI was considered to be established if the 95% confidence interval (CI) for the mean difference in morning PEF was within the prespecified equivalence limits of −15 and +15 l/min, as described previously (27). Assuming a standard deviation of 40 l/min, there was 90% probability of this CI being contained within these limits given that the actual difference was <1.5 l/min. Results of the secondary analysis were not adjusted for multiplicity but a per-protocol (stability) analysis (excluding patients who violated the inclusion/exclusion or randomisation criteria) was performed to confirm the therapeutic equivalence data.

Diary-card end-points, averaged over available data, were analysed using a validated analysis of variance (ANOVA) model with treatment and country as fixed factors and the run-in mean (last 10 days) as a covariate. FEV₁ and AQLQ(S) were also analysed using an ANOVA model with treatment and country as fixed factors and the randomisation value as a covariate. Safety variables were analysed using descriptive statistics.

Results
Patients
A total of 892 patients were enrolled and 680 were subsequently randomised to study treatment (217 to budesonide pMDI, 229 to budesonide/formoterol DPI and 234 to budesonide/formoterol pMDI). The ITT and safety populations comprised 679 patients (one patient in the budesonide/formoterol pMDI group was lost to follow-up). For the primary analysis, 216, 223 and 229 patients in the budesonide pMDI, budesonide/formoterol DPI and budesonide/formoterol pMDI groups, respectively, had morning PEF data from both the run-in and the treatment period. Six hundred patients completed the study; discontinuations were comparable between the three treatment groups (29, 23 and 27 for budesonide pMDI, budesonide/formoterol DPI and budesonide/formoterol pMDI, respectively).

Patients’ demographics and baseline characteristics were well balanced across the three treatment groups (Table 1). In total, 109 (16%) patients were aged 12–17 years, 520 (76%) were aged 18–64 years and 51 (8%) were aged ≥65 years; the distribution of adolescent and elderly patients was even across the three groups. Self-reported adherence to study medication (percentage of diary-logged days on which study medication was used) was equally high across all the three treatment groups (>98%).
Efficacy

Budesonide/formoterol DPI and budesonide/formoterol pMDI improved morning PEF compared with budesonide pMDI (p < 0.001 for both) (Figure 1). Following treatment, the adjusted mean change in morning PEF was 31.4 and 28.6 l/min higher in the budesonide/formoterol DPI and budesonide/formoterol pMDI groups, respectively, than in the budesonide pMDI group. Analysis of improvements from baseline in morning PEF with budesonide/formoterol DPI and budesonide/formoterol pMDI established that the two treatments were therapeutically equivalent (Table 2). A stability analysis of improvements from baseline in morning PEF in the per-protocol population confirmed the therapeutic equivalence of the two budesonide/formoterol inhalation devices; the adjusted mean difference between budesonide/formoterol pMDI and budesonide/formoterol DPI was −4.9 l/min (95% CI: −12.8 to 3.0; p = 0.22).

All secondary diary end-points were improved to a greater extent with budesonide/formoterol DPI and budesonide/formoterol pMDI than with budesonide pMDI (Table 3; Figure 2). For most end-points, the improvements seen with budesonide/formoterol pMDI were similar to those observed with budesonide/formoterol DPI, with the exception of symptom-free and asthma-control days, which were increased by a slightly greater degree with budesonide/formoterol DPI.

### Table 1 Patient demographics and baseline characteristics

| Characteristic                          | Budesonide pMDI (n = 217) | Budesonide/formoterol DPI (n = 229) | Budesonide/formoterol pMDI (n = 234) |
|----------------------------------------|-----------------------------|------------------------------------|-------------------------------------|
| Males/females, n                       | 68/149                      | 89/140                             | 94/140                              |
| Mean age (range), years                | 40 (12–79)                  | 39 (11–78)*                        | 40 (12–78)                         |
| Smokers, n (%)                         | 14 (6)                      | 11 (5)                             | 13 (6)                              |
| Median time since diagnosis (range), years† | 10 (0–70)                  | 9 (1–63)                           | 8 (1–58)                           |
| Mean morning PEF (range), l/min        | 318 (109–638)               | 321 (93–668)                       | 326 (89–715)                       |
| **Mean FEV₁ (range)**                  |                             |                                    |                                     |
| % predicted†                           | 71 (45–91)                  | 69 (50–90)                         | 71 (39–92)                         |
| 1                                       | 2.01 (0.85–4.25)            | 2.09 (1.05–3.75)                   | 2.07 (0.94–4.12)                   |
| Mean ICS at entry (range), µg/day†    | 759 (400–1600)              | 774 (500–1600)                     | 776 (400–1600)                     |
| LABA use at entry, n (%)               | 32 (15)                     | 33 (14)                            | 30 (13)                            |
| Reliever medication use (range), inhalations/day | 2.0 (0.0–14.5) | 1.8 (0.0–11.3)                      | 2.1 (0.0–11.4)                     |
| Reliever medication-free days (range), % | 29 (0–100)                  | 34 (0–100)                         | 29 (0–100)                         |
| Total asthma symptom score (range), 0–6 | 2.1 (0.4–5.7)              | 2.0 (0.0–6.0)                      | 1.9 (0.0–5.3)                      |
| Nights with awakenings (range), %      | 33.1 (0–100)                | 32.1 (0–100)                       | 29.2 (0–100)                       |
| Symptom-free days (range), %           | 10 (0–80)                   | 12 (0–100)                         | 12 (0–100)                         |
| Asthma-control days (range), %         | 8 (0–80)                    | 10 (0–89)                          | 10 (0–100)                         |
| AQLQ(S) (range), 1–7                   | 4.80 (1.8–6.8)              | 4.62 (1.8–7.0)                     | 4.70 (1.4–7.0)                     |

*One patient was 11 years and 354 days old at the enrolment visit. †Deviations from inclusion criteria not considered sufficiently significant to justify exclusion of data from the full analysis. AQLQ(S), Asthma Quality of Life Questionnaire (standardised version); DPI, dry-powder inhaler; FEV₁, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; PEF, peak expiratory flow; pMDI, pressurised metered-dose inhaler.

![Figure 1](image.png)
Consistent with improvements in diary end-points, both budesonide/formoterol DPI and budesonide/formoterol pMDI also improved FEV$_1$ compared with budesonide pMDI (Figure 3), with no significant difference between the two budesonide/formoterol devices.

**Health-related quality of life**

Budesonide/formoterol DPI and budesonide/formoterol pMDI provided similar clinically relevant improvements in health-related quality of life (Figure 4). These improvements with budesonide/formoterol DPI and budesonide/formoterol pMDI were statistically greater than those provided by budesonide pMDI [adjusted mean change in AQLQ(S) overall score: +0.76 (p < 0.001 vs. budesonide pMDI), +0.65 (p = 0.002 vs. budesonide pMDI) and +0.37, respectively]. For the overall AQLQ(S) score, 52% and 56% of budesonide/formoterol pMDI-treated and budesonide/formoterol DPI-treated patients, respectively, had a clinically relevant increase of ≥ 0.5 units compared with 35% of patients in the budesonide pMDI group.

**Safety**

There were no clinically important differences between treatment groups with regard to adverse events [overall (Table 4) and ICS- and $\beta_2$-agonist-related events (Table 5)], vital signs or laboratory parameters. Only 32% of patients experienced one or more adverse events, the majority of which were mild or moderate in severity. Four patients reported serious adverse events: two in the budesonide pMDI group (joint dislocation/accident/fracture, asthma aggravated) and two in the budesonide/formoterol pMDI group (menorrhagia, increase in liver enzyme activity); none were considered (after follow-up) to be related to study treatment. No deaths were reported.

Thirty patients (15 in the budesonide pMDI group, four in the budesonide/formoterol DPI group and 11 in the budesonide/formoterol pMDI group) reported a clinically relevant increase of ≥ 0.5 units compared with patients in the budesonide pMDI group. These improvements were statistically greater than those provided by budesonide pMDI [adjusted mean change in AQLQ(S) overall score: +0.76 (p < 0.001 vs. budesonide pMDI), +0.65 (p = 0.002 vs. budesonide pMDI) and +0.37, respectively]. For the overall AQLQ(S) score, 52% and 56% of budesonide/formoterol pMDI-treated and budesonide/formoterol DPI-treated patients, respectively, had a clinically relevant increase of ≥ 0.5 units compared with 35% of patients in the budesonide pMDI group.

**Table 2** Therapeutic equivalence of budesonide/formoterol DPI and budesonide/formoterol pMDI

| Comparison | Adjusted mean difference | 95% CI | p-value |
|------------|--------------------------|--------|---------|
| Budesonide/formoterol pMDI vs. budesonide/formoterol DPI | -2.8 | -10.4 to 4.9* | 0.48 |
| Budesonide/formoterol pMDI vs. budesonide pMDI | 28.6 | 20.9–36.4 | < 0.001 |
| Budesonide/formoterol DPI vs. budesonide pMDI | 31.4 | 23.7–39.2 | < 0.001 |

*Therapeutic equivalence was defined as a 95% CI for the difference in morning PEF between budesonide/formoterol pMDI and budesonide/formoterol DPI within the range −15 to +15 l/min. CI, confidence interval; DPI, dry-powder inhaler; PEF, peak expiratory flow; pMDI, pressurised metered-dose inhaler.

**Table 3** Changes in secondary diary end-points following treatment with budesonide pMDI, budesonide/formoterol DPI or budesonide/formoterol pMDI

| Variable | Budesonide pMDI (n = 217) | Budesonide/formoterol DPI (n = 229) | Budesonide/formoterol pMDI (n = 233) |
|----------|---------------------------|-----------------------------------|------------------------------------|
| Evening PEF, l/min | −0.6 | 25.1* | 24.3* |
| Reliever medication use, no. of inhalations/24 h | −0.35 | −0.92* | −0.94* |
| Reliever medication-free days, % | 17.9 | 31.1* | 30.8* |
| Total asthma symptom score, 0–6 | −0.44 | −0.84* | −0.70* |
| Nights with awakenings, % | −9.7 | −15.5† | −16.5* |
| Symptom-free days, % | 19.1 | 34.2**†† | 28.0† |
| Asthma-control days, % | 18.3 | 33.1**†† | 26.5† |

*p < 0.001, †p < 0.01 vs. budesonide pMDI; ††p < 0.05 budesonide/formoterol DPI vs. budesonide/formoterol pMDI. DPI, dry-powder inhaler; PEF, peak expiratory flow; pMDI, pressurised metered-dose inhaler.
group) discontinued the study because of adverse events. The most frequently reported adverse event causing discontinuation was asthma aggravated (seven, two and one patient(s) in the budesonide pMDI, budesonide/formoterol DPI and budesonide/formoterol pMDI groups, respectively). Other adverse events leading to discontinuation included nausea, tremor, palpitations and lower respiratory tract infection.

**Discussion**

Budesonide/formoterol, which is available as a DPI, has been reformulated as an HFA pMDI to enable delivery of this effective and well-tolerated therapy via two different devices that meet the needs and requirements of both patients and clinicians alike without detriment to the environment. This large-scale, international, double-blind, double-dummy study set out to compare the efficacy and safety of this novel pMDI formulation of budesonide/formoterol with that of the established DPI, budesonide/formoterol Turbuhaler®, and budesonide pMDI in adults and adolescents with inadequately controlled asthma.

Analysis of the primary end-point – morning PEF – demonstrated that both budesonide/formoterol therapies are more effective than budesonide pMDI.
Table 4 Most frequently reported adverse events

| No. of patients (%)* | Budesonide pMDI (n = 217) | Budesonide/formoterol DPI (n = 229) | Budesonide/formoterol pMDI (n = 233) |
|----------------------|-----------------------------|-------------------------------------|--------------------------------------|
| Patients with ≥ 1 event | 82 (38) | 66 (29) | 70 (30) |
| Nasopharyngitis | 17 (8) | 6 (3) | 4 (2) |
| Upper respiratory tract infection | 9 (4) | 9 (4) | 7 (3) |
| Pharyngitis | 7 (3) | 8 (3) | 4 (2) |
| Lower respiratory tract infection | 6 (3) | 4 (2) | 2 (1) |
| Headache | 4 (2) | 4 (2) | 4 (2) |
| Influenza | 5 (2) | 2 (1) | 4 (2) |
| Wheezing | 5 (2) | 3 (1) | 2 (1) |
| Oral candidiasis | 3 (1) | 5 (2) | 2 (1) |
| Cough | 5 (2) | 2 (1) | 3 (1) |
| Asthma aggravated | 7 (3) | 2 (1) | 1 (< 0.5) |

*Only adverse events reported for ≥ 10 patients in total are included. DPI, dry-powder inhaler; pMDI, pressurised metered-dose inhaler.

Table 5 Incidence of adverse events related to treatment with β₂-agonists or ICS

| No. of patients (%) | Budesonide pMDI (n = 217) | Budesonide/formoterol DPI (n = 229) | Budesonide/formoterol pMDI (n = 233) |
|----------------------|-----------------------------|-------------------------------------|--------------------------------------|
| ICS-related adverse events | | | |
| Dysphonia | 1 (< 0.5) | 2 (1) | 1 (< 0.5) |
| Oral candidiasis | 3 (1) | 5 (2) | 2 (1) |
| β₂-agonist-related adverse events | | | |
| Tremor | 1 (< 0.5) | 2 (1) | 0 |
| Palpitation | 0 | 6 (3) | 1 (< 0.5) |
| Headache | 4 (2) | 4 (2) | 4 (2) |

DPI, dry-powder inhaler; ICS, inhaled corticosteroid; pMDI, pressurised metered-dose inhaler.
The magnitude of improvement in morning PEF with both budesonide/formoterol therapies was within the range of that reported previously for budesonide/formoterol DPI (2,17,28,29), thus verifying the results of the present study. Furthermore, the analysis of the secondary objective demonstrated that, for improvements in morning PEF, budesonide/formoterol pMDI is therapeutically equivalent to budesonide/formoterol DPI.

Analysis of other efficacy end-points relating to lung function, asthma symptoms, disease control and health-related quality of life supports the comparable efficacy of budesonide/formoterol pMDI with budesonide/formoterol DPI and the superiority of both formulations over budesonide pMDI. The only statistical differences between the two devices – which favoured budesonide/formoterol DPI – were in the composite end-points: symptom-free days and asthma-control days. In both cases, differences were driven by the additional improvement in daytime total asthma symptom score (data not shown). Previous studies report that the degree of lung deposition for the DPI device is approximately 2–3 times that of the corresponding pMDI device (30–32) and hence it is possible that this may have contributed to the significant differences in symptom-free days and asthma-control days observed in this study. However, there is no existing literature regarding the relative degree of lung deposition for budesonide/formoterol DPI or pMDI and as the degree of lung deposition varies for different DPIs and pMDIs it cannot be assumed that Turbuhaler DPI will deliver 2–3 times more drug to the lungs when compared with a pMDI (33). Instead it is more likely that any improvements in asthma symptoms associated with DPI are due to random variation and a much larger study would be required to detect a clear difference in outcome for these variables. Furthermore, as there were no differences between the two devices in end-points such as nighttime awakenings, 24-h total asthma symptom scores and reliever medication use (markers of asthma control), and in the number of adverse events reported as asthma aggravated (an indicator of more severe events), it is unlikely that the difference in daytime symptom variables is clinically important. Interestingly, the improvements in lung function and symptom-related end-points with both budesonide/formoterol therapies appeared to be progressive, with the evidence of continuing improvement between weeks 2 and 6 (Figures 1–3). Conversely, but perhaps not unexpectedly, there appeared to be little evidence of progressive improvement with budesonide pMDI in this patient population. As previously reported in comparative studies of budesonide/formoterol DPI vs. budesonide DPI (2,18,34,35), and as would be expected for an ICS (1), budesonide pMDI improved asthma symptoms, measures of asthma control and health-related quality of life, but these improvements were smaller than those seen with the budesonide/formoterol therapies.

In the clinical setting, choice of inhaler device is less likely to depend on efficacy and tolerability and is more likely to be influenced by other factors, for example cost, the patient’s ability to use the selected device correctly and personal preference (36). DPI devices are generally more expensive than pMDIs and the therapeutic equivalence observed between the delivery devices suggests that either would be suitable for use in normal clinical practice. Besides cost, differences in ease of use and technique between pMDI and the DPI are likely to have a large influence on choice of inhaler for individual patients and clinicians. Although both devices are relatively easy to use, each has technical limitations which can limit effectiveness (37). In this study patients were instructed on how to use the inhalers correctly at visit 1. Each participating study site was provided with a DPI/pMDI to be used with disposable mouthpieces/actuators, allowing patients to practise the inhalation technique. Furthermore, results report that compliance (study drug use measured by self-reported diary recording of daily treatment intake) was similar across all treatment groups. Thus, it is unlikely that patients randomised to receive the pMDI inhaler had any disadvantages compared with those using the DPI with regard to inhaler technique. In the clinical setting, providing each individual with the most appropriate inhaler has the potential to result in more effective patient care (37).

In terms of safety, budesonide/formoterol pMDI, budesonide/formoterol DPI and budesonide pMDI were well tolerated, with a low overall incidence of adverse events across the three treatment groups. Adverse events were slightly more common in the budesonide pMDI group – although this was not thought to be clinically relevant – and the majority of patients who reported aggravated asthma as an adverse event were in this treatment group. Importantly, the tolerability profiles of both budesonide/formoterol therapies were similar to that reported previously for budesonide/formoterol DPI (29).

In conclusion, this study demonstrates that budesonide/formoterol, administered via the HFA pMDI or DPI, is an effective and well-tolerated treatment for adult and adolescent patients with asthma, with both devices being therapeutically equivalent. The availability of both devices will give clinicians greater freedom to select a cost-effective therapy that suits
the needs and preferences of individual patients and clinicians themselves.

Acknowledgements

We would like to thank all the study investigators for their exceptional work in conducting the trial. We would also like to thank Lena Laxmyr (AstraZeneca R&D, Lund, Sweden), who prepared the study outline with great enthusiasm. In addition, we would like to express our thanks to Mark Richardsson (Adelphi Communications Ltd), who provided medical writing support on behalf of AstraZeneca. This study was funded by AstraZeneca R&D, Lund, Sweden.

References

1 National Institutes for Health. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. GINA Workshop Report. Bethesda, MD: National Institutes for Health, NIH Publication No. 02-3659, 1995 (updated 2004).
2 Buhl R, Creemers JP, Vondra V et al. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 2003; 97: 323–30.
3 Stallberg B, Olsson P, Jorgensen LA et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003; 57: 656–61.
4 Fitzgerald JM, Sears MR, Boulet LP et al. Adjustable maintenance dosing reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003; 10: 427–34.
5 O’Byrne PM, Biegzaed H, Godard PP et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129–36.
6 Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403–18.
7 Rabe KF, Pizzicichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129: 246–56.
8 Seberova E, Andersson A. Otxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI, Respir Med 2000; 94: 607–11.
9 Palmqvist M, Persson G, Lazer L et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484–9.
10 Miller-Larsson A, Mattsson H, Hjertberg E et al. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topical sodium steroid in airway tissue. Drug Metab Dispos 1998; 26: 623–30.
11 Miller-Larsson A, Jansson P, Runstrom A et al. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000; 162: 1455–61.
12 Thorsson L, Thunnessen FRJ, Korn S et al. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo [abstract]. Am J Respir Crit Care Med 1998; 157 (Suppl. 3): A404.
13 Balazag VM, Yunus F, Yang FC et al. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Palm Pharmacol Ther 2006; 19: 139–47.
14 Busse WW, Cherninsky P, Condemni J et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101: 457–63.
15 Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 2000; 117: 440–6.
16 Palmqvist M, Ibsen T, Mellen A et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244–9.
17 Aalbers R, Backer V, Kava TT et al. Adjusted maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/ﬂuticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20: 225–40.
18 Pohl WR, Vetter N, Zwick H et al. Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study. Respir Med 2006; 100: 551–60.
19 Vogelmeier C, D’Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819–28.
20 Ross DL, Gabriol BJ. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. J Aerosol Med 1999; 12: 151–60.
21 Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care 2005; 50: 1201–8.
22 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225–44.
23 Juniper EF, Buist AS, Cox FM et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115: 1265–70.
24 Polgar G, Promadhavat H. Maximal airflow rates. In: Polgar G, ed. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia, PA: W. B. Saunders Company, 1971: 170–95.
25 Quaas JH, Tammeling GJ, Cotes JE et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Ofﬁcial Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5–40.
26 Juniper EF, Guyatt GH, Willan A et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81–7.
27 Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001; 95: 136–46.
28 Bateman ED, Bjeris TA, Joao Gomes M et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Crit Care Med 2003; 167: 440–6.
29 Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004; 64: 1597–618.
30 Borgstrom L, Derom E, Stahl E et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636–40.
31 Thorsson L, Edsbakker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7: 1839–44.
32 Selroos O, Borgstrom L, Ingelf J. Performance of Turbuhaler ((R)) in patients with acute airway obstruction and COPD, and in children with asthma: understanding the clinical importance of adequate peak inspiratory flow, high lung deposition, and low in vivo dose variability. Treat Respir Med 2006; 5: 303–15.
33 Thorsson L, Edsbakker S, Kalten A et al. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52: 529–38.
34 Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. *Eur Resp J* 2001; 18: 262–8.

35 Tal A, Simon G, Vermeulen JH et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. *Pediatr Pulmonol* 2002; 34: 342–50.

36 Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* 2005; 127: 353–71.

37 Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. *Respir Care* 2005; 50: 1360–74.